Haynes Boone represented RedHill in the transaction. RedHill Biopharma Ltd. (NASDAQ: RDHL) announced an exclusive worldwide development and commercialization licensing agreement, excluding North America, for its...
You must be a Standard 1 Year member to access this content.
Haynes Boone advised e2Companies LLC on the deal, Vinson & Elkins advised Nabors Energy Transition Corp. II, and Milbank LLP advised Nabors. e2Companies LLC announced its...
You must be a Standard 1 Year member to access this content.
Haynes and Boone represented NRX Pharmaceuticals, Inc. in the offering, and Sichenzia Ross Ference Carmel represented EF Hutton. NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), (“NRx Pharmaceuticals” or...
You must be a Standard 1 Year member to access this content.
Haynes and Boone, LLP is representing Firefly Neuroscience, Inc. in the transaction, and Greenberg Traurig is representing WaveDancer, Inc. Firefly Neuroscience, Inc. (“Firefly”) announced it has...
You must be a Standard 1 Year member to access this content.
Haynes and Boone, LLP represented LadRx Corporation, while Gibson, Dunn & Crutcher LLP represented XOMA (US) LLC. LadRx announced that it has transferred the royalty and milestone...
You must be a Standard 1 Year member to access this content.
Haynes and Boone represented Enveric Biosciences in the transaction. Enveric Biosciences (NASDAQ: ENVB) executed its acquisition of MagicMed Industries Inc., a privately-held biotechnology company focused on...
You must be a Standard 1 Year member to access this content.
Haynes and Boone represented Gold Royalty Corp. in the offering. Gold Royalty Corp. executed its $90 million initial public offering and listing on the NYSE American....
You must be a Standard 1 Year member to access this content.
